We are live on
!
Find out more
SAM
Senzar Asset Management Portfolio holdings
AUM
$34.7M
1-Year Est. Return
0.56%
This Fund
S&P 500
This Quarter
Est. Return
+12.1%
1 Year Est. Return
+0.56%
3 Year Est. Return
-0.75%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$341M
AUM Growth
+$160K
(+0.05%)
Cap. Flow
-$29.8M
Cap. Flow
% of AUM
-8.73%
Top 10 Holdings %
Top 10 Hldgs %
53.88%
Holding
39
New
10
Increased
16
Reduced
6
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bausch Health
BHC
|
+$20.2M |
| 2 |
AGN
Allergan plc
AGN
|
+$17.9M |
| 3 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
+$11.4M |
| 4 |
Ironwood Pharmaceuticals
IRWD
|
+$10.7M |
| 5 |
Sanofi
SNY
|
+$10.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
GSK
GSK
|
+$30.7M |
| 2 |
AbbVie
ABBV
|
+$24.9M |
| 3 |
Enanta Pharmaceuticals
ENTA
|
+$23.4M |
| 4 |
Teva Pharmaceuticals
TEVA
|
+$18.8M |
| 5 |
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
|
+$17.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 85.82% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Talphera
TLPH
$67M
| $6.1M | 1.79% |
45,339
+17,644
| +64% | +$2.29M |
|
27
Rigel Pharmaceuticals
RIGL
$710M
| $4.81M | 1.41% |
211,799
+4,359
| +2% | +$88.2K |
|
|
FOMX
28
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
| $3.59M | 1.05% |
+512,649
| New | +$2.93M |
|
|
BLUE
29
DELISTED
bluebird bio
BLUE
| $3.46M | 1.01% |
+2,910
| New | +$1.94M |
|
|
VXRT
30
DELISTED
Vaxart
VXRT
| $3.15M | 0.92% |
127,973
+118,982
| +1,323% | +$3.05M |
|
|
ELOS
31
DELISTED
Syneron Medical Ltd
ELOS
| $2.81M | 0.82% |
+301,100
| New | +$2.9M |
|
|
32
Enanta Pharmaceuticals
ENTA
$366M
| $2.24M | 0.66% |
44,117
-522,786
| -92% | -$23.4M |
|
|
33
AbbVie
ABBV
$469B
| – | – |
-431,400
| Closed | -$24.9M |
|
|
34
GSK
GSK
$106B
| – | – |
-534,560
| Closed | -$30.7M |
|
35
Medtronic
MDT
$112B
| – | – |
-238,100
| Closed | -$14.8M |
|
|
RAD
36
DELISTED
Rite Aid Corporation
RAD
| – | – |
-61,700
| Closed | -$5.97M |
|
|
WCG
37
DELISTED
Wellcare Health Plans, Inc.
WCG
| – | – |
-75,700
| Closed | -$4.57M |
|
|
KYTH
38
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
| – | – |
-66,300
| Closed | -$2.17M |
|
|
AGN
39
DELISTED
Allergan Inc
AGN
| – | – |
-57,300
| Closed | -$10.2M |
|
Similar funds
BCP
PRHC
NAM
GG
SM
BC
SCPM
FAM
Senzar Asset Management's Q4 2014 Portfolio in Review
As of Q4 2014, Senzar Asset Management held 39 positions worth $341M, up 0.05% from $341M the previous quarter. Its ten largest holdings account for 54% of the portfolio.
Senzar Asset Management withdrew a net $29.8M in Q4 2014, closing 7 positions and reducing 6 holdings. Its most notable exit was GSK, an estimated $30.7M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 92% a quarter earlier.
Against the trend, Senzar Asset Management opened a new position in Bausch Health worth $21.5M.
- Senzar Asset Management's largest Q4 2014 buy was Bausch Health: 150,300 shares worth $21.5M.
- Senzar Asset Management added most to Sanofi in Q4 2014, an estimated $10.5M increase.
- Senzar Asset Management's biggest Q4 2014 reduction was Enanta Pharmaceuticals, cutting an estimated $23.4M.
- Senzar Asset Management fully exited GSK in Q4 2014, selling an estimated $30.7M.
- Senzar Asset Management's ten largest holdings make up 54% of its $341M portfolio in Q4 2014.
- Senzar Asset Management opened 10 new positions and closed 7 in Q4 2014.
- Senzar Asset Management's portfolio value rose 0.05% quarter-over-quarter to $341M.
Based on Senzar Asset Management's 13F filing for Q4 2014, filed 17 Feb 2015.